Showing 4551-4560 of 5659 results for "".
- ACAAI News: 72% of AD Patients Report Poor Mental Health for 1-10 Days in the Past Monthhttps://practicaldermatology.com/news/acaai-news-72-of-ad-patients-report-poor-mental-health-for-1-10-days-in-the-past-month/2462129/Folks with atopic dermatitis (AD) are more likely to report poor mental health than their counterparts without the inflammatory skin condition, new research shows. The study, which was presented at the 2023 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientif
- Super Melanin May Heal Skin Injuries From Sunburn, Chemical Burnshttps://practicaldermatology.com/news/super-melanin-may-heal-skin-injuries-from-sunburn-chemical-burns/2462125/A synthetic, biomimetic melanin may heal the damage that occurs when your skin is exposed to sunlight or environmental toxins. In a new study, Northwestern University scientists show that their synthetic melanin, mimicking the natural melanin in human skin, can be applied
- ACR: TREMFYA Improves Pain, Physical Function and Fatigue in PsA Patients Through Six Monthshttps://practicaldermatology.com/news/acr-tremfya-improves-pain-physical-function-and-fatigue-in-psa-patients-through-six-months/2462121/Substantial numbers of people living with treatment-resistant active PsA who used TREMFYA (guselkumab) in real-world settings reported meaningful improvements in pain, physical function and fatigue through six months, according to new data from the CorEvitas Psoriatic Arthritis (PsA) and Spo
- Biosimilar News: FDA Approves Stelara Biosimilar Wezlanahttps://practicaldermatology.com/news/biosimilar-news-fda-approves-stelara-biosimilar-wezlana/2462118/The U.S. Food and Drug Administration (FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Stelara (ustekinumab) for psoriasis and multiple other inflammatory diseases. The FDA granted the approval of Wezlana to Amgen, Inc. Wezlana, like Stelar
- ‘Bliss’ Compound May Hold Out Hope for Autoimmune Skin Diseasehttps://practicaldermatology.com/news/bliss-compound-may-hold-out-hope-for-autoimmune-skin-disease/2462112/A marijuana-like compound holds out promise as a new treatment for a severe autoimmune skin disease called skin lupus, suggests a recent study out of George Washington University. If the results of the mouse study can be replicated in human trials, the compound, known as anandamide
- Positive Clinical Data Show Potential of STP705 for Focal Fat Reductionhttps://practicaldermatology.com/news/sirnaomics-presents-positive-clinical-data-of-stp705-for-focal-fat-reduction/2462111/New data for the investigative STP705 injectible for focal fat reduction (FFR) are "encouraging," according to the manufacturer, who presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22–25 in Las Vegas. The safety an
- Study Validates Long-Term Safety of Delgocitinib Cream in Adults With Chronic Hand Eczemahttps://practicaldermatology.com/news/study-validates-long-term-safety-of-delgocitinib-cream-in-adults-chronic-hand-eczema/2462105/LEO Pharma’s Delgocitinib Cream was well-tolerated in adults with moderate to severe chronic hand eczema (CHE), according to results from the DELTA 3 Open-Label Extension Trial. What’s more, patients who entered the DELTA 3 trial after receiving delgocitinib cream
- Breaking News From Fall Clinical: Lebrikizumab Performs Well for Up to Two Years in ADhttps://practicaldermatology.com/news/ears-experienced-sustained-skin-clearance-itch-relief-and-reduced-disease-severity-with-monthly-maintenance-dosing-as-demonstrated-in-the-adjo/2462083/Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing, according to data from the ADjoin long-term extensi
- Exploring OX40’s Role in AD: A Conversation With Dr. Stephan Weidingerhttps://practicaldermatology.com/news/exploring-ox40s-role-in-ad-a-conversation-with-dr-stephan-weidinger/2462078/The anti-Ox40-ligand antibody amlitelimab performed well in the phase 2b Stream-AD trial of adults with moderate-to-severe atopic dermatitis, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. Amlitelimab demonstrated c
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.